James Hambro & Partners LLP Raises Stock Holdings in Eli Lilly and Company (NYSE:LLY)

James Hambro & Partners LLP boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 3.7% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 340 shares of the company’s stock after purchasing an additional 12 shares during the period. James Hambro & Partners LLP’s holdings in Eli Lilly and Company were worth $301,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. M&G Plc acquired a new stake in Eli Lilly and Company during the first quarter valued at approximately $8,896,000. Virtu Financial LLC acquired a new stake in Eli Lilly and Company during the first quarter valued at approximately $2,138,000. China Universal Asset Management Co. Ltd. raised its stake in Eli Lilly and Company by 19.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after buying an additional 1,620 shares in the last quarter. Mutual Advisors LLC raised its stake in Eli Lilly and Company by 404.8% during the first quarter. Mutual Advisors LLC now owns 62,598 shares of the company’s stock valued at $48,699,000 after buying an additional 50,197 shares in the last quarter. Finally, Private Advisor Group LLC raised its stake in Eli Lilly and Company by 0.6% during the first quarter. Private Advisor Group LLC now owns 76,282 shares of the company’s stock valued at $59,345,000 after buying an additional 430 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on LLY. Wells Fargo & Company increased their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research report on Friday, August 9th. Sanford C. Bernstein began coverage on Eli Lilly and Company in a research report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price target on the stock. JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Bank of America increased their price target on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,002.24.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $906.13 on Tuesday. The stock has a fifty day moving average price of $921.65 and a two-hundred day moving average price of $859.57. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The firm has a market cap of $861.19 billion, a P/E ratio of 133.45, a PEG ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a 1 year low of $547.61 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping the consensus estimate of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. Research analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.